A new lentiviral gene therapy for methylmalonic acidemia (MMA) has demonstrated the ability to provide long-term metabolic correction in preclinical models, according to researchers at Genespire and the San Raffaele Telethon Institute for Gene Therapy (SR-TIGET). The experimental treatment, designed to target liver cells, achieved sustained improvements in metabolic biomarkers throughout the average lifespan of laboratory mice, marking a potential path toward human clinical trials for the rare, life-limiting metabolic disorder.
Understanding Methylmalonic Acidemia
MMA is a severe inherited metabolic condition typically caused by mutations in the gene responsible for the enzyme methylmalonyl-CoA mutase (MUT). This enzyme is critical for breaking down specific fats and proteins. When the enzyme fails to function, methylmalonic acid builds up in the bloodstream, leading to progressive damage to the kidneys, liver, and brain.
Currently, there are no approved disease-targeted medicines for MMA. Patients often face severe complications and significant illness. The experimental gene therapy, known as GENE202, aims to address the root cause by delivering a healthy copy of the MMUT gene directly to liver cells using a lentiviral vector.
Did you know? The study indicates that the GENE202 approach maintains its effectiveness as the liver grows and matures after birth.
Preclinical Breakthroughs and Gene Delivery
The research team, led by Dr. Alessio Cantore of SR-TIGET and Vita-Salute San Raffaele University, utilized an optimized version of the MMUT transgene to improve efficacy. Data from the study showed that this approach successfully achieved gene transfer in more than 80 percent of liver cells in the mouse model.
The findings suggest that healthy, genetically corrected liver cells may gradually replace diseased cells over time. According to the researchers, this process could allow the therapy to become more effective as time passes, potentially requiring lower initial doses to achieve long-term metabolic stability.
Path Toward Clinical Trials
Genespire’s leadership views these results as a foundational step for human health. “We believe our approach has the potential to translate into human health in the form of a single-administration treatment,” said Lucia Faccio, CEO of Genespire. The company is currently focused on advancing GENE202 toward clinical testing.
Dr. Cantore noted that the comprehensive preclinical data package is intended to support the initiation of clinical trials in pediatric patients. While the current results are confined to animal studies, they provide a framework for future human testing to confirm safety and clinical effectiveness.
Frequently Asked Questions
What is the primary goal of the GENE202 therapy?
The therapy aims to deliver a functional version of the MMUT gene to the liver to restore the body’s ability to break down proteins and fats, preventing the toxic buildup of methylmalonic acid.
How does this therapy differ from current treatment options?
There are currently no approved disease-targeted medicines for MMA. Unlike standard supportive care, this gene therapy is designed as a single-administration treatment to provide a durable correction of the underlying genetic defect.
When will this treatment be available to patients?
The therapy is still in the preclinical stage. Further studies are required to confirm safety and efficacy in humans before it can move through the clinical trial process.
Stay Informed
Are you interested in the latest developments in gene therapy for rare diseases? Subscribe to our newsletter for monthly updates on clinical trials and biotechnology breakthroughs.
